Project Grant R01HL182737
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $769K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38103, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Tennessee Health Science Center $253,395 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify genetic modifiers of acute kidney injury in sickle cell disease. The award funds research evaluating candidate genetic variants—apolipoprotein L1 (APOL1), hemeoxygenase-1 (HMOX1), BCL11A, and alpha thalassemia—for their association with acute kidney injury (AKI) in a well-genotyped and...
- The National Heart, Lung, and Blood Institute awarded the University of Utah $705,239 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on PET imaging as a tool to define mechanisms and stratify risk in arrhythmogenic cardiomyopathy. The recipient will integrate molecular imaging, immune profiling, and cardiac physiology in mechanistically relevant mouse models to test the hypothesis that positron emission tomography using...
- The National Heart, Lung, and Blood Institute awarded Florida State University $703,101 on July 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to establish the role of structural elements in cardiac muscle contraction. The project addresses understudied functional regions of cardiac troponin C (CTNC), the calcium-binding subunit of the troponin complex that regulates calcium-dependent myofilament activation. The research targets cardiomyopathies arising from...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $856,721 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop flecainide analogs that selectively inhibit the cardiac ryanodine receptor (RYR2) for arrhythmia prevention. The project addresses a critical gap in antiarrhythmic therapy. Sudden cardiac death from ventricular arrhythmias accounts for 10–20 percent of adult deaths in the United States, and implantable...
- The National Heart, Lung, and Blood Institute awarded Geisinger Clinic $823,655 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to assemble and harmonize genomic and phenotypic data across three large biobanks—MyCode at Geisinger, BioVU, and the UK Biobank—approaching one million individuals to understand the disease spectrum and clinical modifiers of titin gene protein-truncating variants (TTNTV) in heritable cardiomyopathy. TTNTV account for roughly 20...
- The National Heart Lung and Blood Institute awarded the University of Pennsylvania $169,020 on April 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the genomic and clinical mechanisms of myocardial lipomatous metaplasia and its prognostic implications for cardiac dysfunction and arrhythmia. The recipient will apply a deep-learning segmentation model to cardiac CT images from the Penn Medicine Biobank (23,940 participants with genotypes and imaging as of...
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $577,065 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the roles of endoplasmic reticulum stress in calcium-dependent cardiac arrhythmias. The research addresses how endoplasmic reticulum stress response contributes to acquired cardiovascular diseases with high arrhythmic risk, particularly those involving hyperactivity of the ryanodine receptor (RYR2), the...
- The National Heart, Lung, and Blood Institute awarded the University of Washington $2.815 million on September 24, 2025, under CFDA 93.837 (Cardiovascular Diseases Research) to conduct proteomic and genomic discovery of molecular targets linked to atrial cardiopathy-related cardiovascular outcomes. The award funds research using proteomics and genomic methods across primary and secondary prevention populations to identify novel proteins that may serve as causal risk factors for atrial...
- The National Heart, Lung, and Blood Institute awarded $108,656 to the University of Wisconsin–Madison on March 3, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize the molecular mechanisms of phospholamban R14DEL cardiomyopathy. The recipient will use high-resolution mass spectrometry–based proteomics, human clinical samples, and patient-specific human induced pluripotent stem cell–derived cardiomyocytes to investigate how cardiac proteoform alterations drive...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $174,621 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac magnetic resonance imaging (CMR) techniques for monitoring congenital heart disease using ultra-low field (ULF) MRI systems. The recipient will adapt CMR to an inexpensive, unshielded, open-geometry ULF MRI system and apply machine learning techniques to mitigate hardware limitations and...